Literature DB >> 19303163

Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis.

Cristina Ripoll1, Roberto J Groszmann, Guadalupe Garcia-Tsao, Jaime Bosch, Norman Grace, Andrew Burroughs, Ramon Planas, Angels Escorsell, Juan Carlos Garcia-Pagan, Robert Makuch, David Patch, Daniel S Matloff.   

Abstract

BACKGROUND/AIMS: A total of 213 patients with compensated cirrhosis, portal hypertension and no varices were included in a trial evaluating beta-blockers in preventing varices. Predictors of the development of hepatocellular carcinoma (HCC), including hepatic venous pressure gradient (HVPG) were analyzed.
METHODS: Baseline laboratory tests, ultrasound and HVPG measurements were performed. Patients were followed prospectively every three months until development of varices or variceal bleeding or end of the study in 09/02. The endpoint was HCC development according to standard diagnostic criteria. Univariate and multivariate Cox regression models were developed to identify predictors of HCC.
RESULTS: In a median follow-up of 58 months 26/213 (12.2%) patients developed HCC. Eight patients were transplanted and 28 patients died without HCC. Twenty-one (84%) HCC developed in patients with HCV. On multivariate analysis HVPG (HR 1.18; 95%CI 1.08-1.29), albumin (HR 0.34; 95%CI 0.14-0.83) and viral etiology (HR 4.59; 95%CI 1.51-13.92) were independent predictors of HCC development. ROC curves identified 10 mmHg of HVPG as the best cut-off; those who had an HVPG above this value had a 6-fold increase in the HCC incidence.
CONCLUSIONS: Portal hypertension is an independent predictor of HCC development. An HVPG >10 mmHg is associated with a 6-fold increase of HCC risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303163      PMCID: PMC3721146          DOI: 10.1016/j.jhep.2009.01.014

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  17 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Alphafetoprotein: an obituary.

Authors:  M Sherman
Journal:  J Hepatol       Date:  2001-04       Impact factor: 25.083

3.  HCC surveillance: who is the target population?

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

Review 4.  Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte?

Authors:  June Sung Lee; David Semela; John Iredale; Vijay H Shah
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

5.  The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients.

Authors:  Angelo Sangiovanni; Gian Maria Prati; Pierangelo Fasani; Guido Ronchi; Raffaella Romeo; Matteo Manini; Ersilio Del Ninno; Alberto Morabito; Massimo Colombo
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

Review 6.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis.

Authors:  R Mazzanti; L Messerini; L Monsacchi; G Buzzelli; A L Zignego; M Foschi; M Monti; G Laffi; L Morbidelli; O Fantappié; F Bartoloni Saint Omer; M Ziche
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

8.  Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

Authors:  F Degos; C Christidis; N Ganne-Carrie; J P Farmachidi; C Degott; C Guettier; J C Trinchet; M Beaugrand; S Chevret
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

9.  Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis.

Authors:  Rosario F Velázquez; Manuel Rodríguez; Carmen A Navascués; Antonio Linares; Ramón Pérez; Nieves G Sotorríos; Isabel Martínez; Luis Rodrigo
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

10.  Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.

Authors:  Cristina Ripoll; Roberto Groszmann; Guadalupe Garcia-Tsao; Norman Grace; Andrew Burroughs; Ramon Planas; Angels Escorsell; Juan Carlos Garcia-Pagan; Robert Makuch; David Patch; Daniel S Matloff; Jaime Bosch
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

View more
  104 in total

1.  Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans.

Authors:  David G Koch; Galina Bogatkevich; Venkat Ramshesh; John J Lemasters; Renan Uflacker; Adrian Reuben
Journal:  Dig Dis Sci       Date:  2011-10-01       Impact factor: 3.199

2.  Portal hypertension in patients with cirrhosis: indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging.

Authors:  Hervé Gouya; Sophie Grabar; Olivier Vignaux; Anastasia Saade; Stanislas Pol; Paul Legmann; Philippe Sogni
Journal:  Eur Radiol       Date:  2015-09-15       Impact factor: 5.315

Review 3.  Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.

Authors:  Andrew H Talal; Charles S Venuto; Islam Younis
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

Review 4.  Duplex Doppler ultrasound examination of the portal venous system: an emerging novel technique for the estimation of portal vein pressure.

Authors:  Ashwani K Singal; Masood Ahmad; Roger D Soloway
Journal:  Dig Dis Sci       Date:  2009-07-23       Impact factor: 3.199

Review 5.  Management of NAFLD: a stage-based approach.

Authors:  Mary E Rinella; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

Review 6.  Invasive and non-invasive diagnosis of cirrhosis and portal hypertension.

Authors:  Moon Young Kim; Woo Kyoung Jeong; Soon Koo Baik
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

7.  Platelet-related phenotypic patterns in hepatocellular carcinoma patients.

Authors:  Brian I Carr; Chih-Yun Lin; Sheng-Nan Lu
Journal:  Semin Oncol       Date:  2014-04-23       Impact factor: 4.929

Review 8.  Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement.

Authors:  Ki Tae Suk; Dong Joon Kim
Journal:  World J Hepatol       Date:  2015-03-27

Review 9.  Pharmacologic prevention of variceal bleeding and rebleeding.

Authors:  Anna Baiges; Virginia Hernández-Gea; Jaime Bosch
Journal:  Hepatol Int       Date:  2017-12-05       Impact factor: 6.047

Review 10.  Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond.

Authors:  Horia Stefanescu; Bogdan Procopet
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.